
Moderna's mRNA-1010 Flu Vaccine Proves Superior Efficacy in Pivotal Late-Stage Trial
Moderna’s investigational mRNA-based seasonal influenza vaccine, mRNA-1010, showed superior efficacy compared to a licensed standard-dose flu vaccine in adults aged 50 and older, according to topline results from the pivotal phase 3 P304 trial. The study …